Oligonucleotides News and Research RSS Feed - Oligonucleotides News and Research

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.
Using single-molecule studies to understand cellular processes: an interview with Professor W. E. Moerner

Using single-molecule studies to understand cellular processes: an interview with Professor W. E. Moerner

Single fluorescent molecules provide a local nanometer-sized probe of complex systems. We can measure the motion of the single molecule, use them to achieve imaging on a scale down to 20 nanometers, or we can infer aspects of the behaviour of the object under study by the details of the light that is emitted. [More]
Study paves way for development of novel cancer therapeutics

Study paves way for development of novel cancer therapeutics

A team of scientists, comprising researchers from the Institute of Molecular and Cell Biology, a research institute under the Agency for Science, Technology and Research, Singapore, and the VIB Laboratory of Molecular Cancer Biology, has revealed the mechanism by which tumor cells elevate levels of MDM4, a protein that is highly expressed in cancer cells but not in normal adult tissues. [More]
IDT’s innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

IDT’s innovative Alt-R CRISPR-Cas9 System improves genome editing potency, reduces cell toxicity

Integrated DNA Technologies, introduces a new approach to CRISPR—its innovative Alt-R CRISPR-Cas9 System, based on the naturally occurring S. pyogenes CRISPR RNA system. [More]
Sense oligonucleotide antidote reverses actions of antisense antithrombotic drug, prevents bleeding

Sense oligonucleotide antidote reverses actions of antisense antithrombotic drug, prevents bleeding

Researchers from Isis Pharmaceuticals (Carlsbad, CA) and Prysis Biotechnologies (Pudong, Shanghai, China) have demonstrated proof-of-concept for using a sense oligonucleotide to undo the effects of an antisense drug, an antithrombotic agent in this novel study. [More]
Study: RNA editing technique shows promise in treating rare, severe form of muscular dystrophy

Study: RNA editing technique shows promise in treating rare, severe form of muscular dystrophy

An RNA editing technique called "exon skipping" has shown preliminary success in treating a rare and severe form of muscular dystrophy that currently has no treatment, based on a new study from Northwestern Medicine and the University of Chicago. Children with the disease lose significant muscle strength early in life. [More]
Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Scientists at the University of California, San Diego School of Medicine have elucidated a genetic interaction that may prove key to the development and progression of glaucoma, a blinding neurodegenerative disease that affects tens of millions of people worldwide and is a leading cause of irreversible blindness. [More]
IDT to host webinar on high throughput qPCR profiling studies

IDT to host webinar on high throughput qPCR profiling studies

Integrated DNA Technologies will be hosting a webinar to help researchers get the most out of gene expression studies that analyze large numbers of samples. [More]
Common gene mutation may cause brain damage associated with ALS and FTD

Common gene mutation may cause brain damage associated with ALS and FTD

Johns Hopkins researchers say they have discovered some of the first steps in how a very common gene mutation causes the brain damage associated with both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). [More]
IDT webinar explores effective RNAi and antisense oligo methods

IDT webinar explores effective RNAi and antisense oligo methods

Integrated DNA Technologies (IDT) will host an informative webinar, entitled ‘Knockdown of lncRNAs: exploring RNAi and antisense oligo methods’, on Tuesday, August 25, 2015. Kim Lennox, a research scientist at IDT and expert in the suppression of gene expression, will present the webinar at 9 am and 1 pm Central Standard Time. [More]
Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. [More]
Innovative approach to treating AAT deficiency

Innovative approach to treating AAT deficiency

Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)--which is missing or nonfunctional in the genetic disorder AAT deficiency--into cells in the laboratory, enabling the cells to produce highly functional AAT. [More]
Novel gene therapy control system regulates expression of therapeutic transgenes

Novel gene therapy control system regulates expression of therapeutic transgenes

Korean researchers have described a novel control system to regulate the expression of a therapeutic transgene by targeting the passenger strand of a microRNA (miR-122) linked to the transgene. [More]
Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"). [More]
Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Researchers have shown that a novel delivery strategy can efficiently introduce a functional microRNA that has anti-cancer and angiogenic activities into two different types of cells--breast cancer cells to inhibit tumor growth and metastasis, and cells that line blood vessels to protect against atherosclerosis. [More]
University of Washington receives PPMD grant to continue analysis of spectrin-like repeats in dystrophin

University of Washington receives PPMD grant to continue analysis of spectrin-like repeats in dystrophin

Parent Project Muscular Dystrophy, a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) awarded University of Washington a $148,000 grant to continue the functional analysis of spectrin-like repeats in dystrophin. [More]
A beginner’s guide to CRISPR genome editing

A beginner’s guide to CRISPR genome editing

In a recent DECODED Online entry, Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, provides an overview of the CRISPR/Cas9 system to scientists looking to enhance their genome modification strategy in model organisms or cell lines. [More]
Experimental oligonucleotide-based drug stimulates human immune system to fight infections

Experimental oligonucleotide-based drug stimulates human immune system to fight infections

An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components. [More]
IDT supports unique bioengineering public outreach program

IDT supports unique bioengineering public outreach program

To help the general public understand how bioengineering is changing the world for the better, Integrated DNA Technologies (IDT) is supporting a unique public outreach program led by expert plant synthetic biologists at Revolution Bioengineering. [More]
Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. [More]
IDT’s CRISPR/Cas9 online resource for all your genome editing needs

IDT’s CRISPR/Cas9 online resource for all your genome editing needs

Integrated DNA Technologies (IDT) has pooled its expertise in genome editing into a free web resource dedicated to providing researchers a hub of information on the very latest in using the CRISPR/Cas9 system. [More]
Advertisement
Advertisement